Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis

Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis

BackgroundOne of the milestones in bacterial-mediated therapy for cancer, Bacillus Calmette-Guerin (BCG) has been used to treat bladder cancer (BC) for more than 30 years. BCG immunotherapy is now the standard of care for high-grade non-muscle invasive bladder cancer (NMIBC) following transurethral...

Full description

Bibliographic Details
Main Authors:	Xingfeng Chen, Fang He, Wenjin Zhang, Yao Fu, Zhiqin Cao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Oncology
Subjects:	BCG immunotherapy immune checkpoint inhibitors web of science bibliometric analysis bladder cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1092969/full

Similar Items

BCG in Bladder Cancer Immunotherapy
by: Song Jiang, et al.
Published: (2022-06-01)

Miliary Tuberculosis Due to BCG Immunotherapy
by: Bilgehan AYGEN, et al.
Published: (1996-03-01)

The Urothelial Transcriptomic Response to Interferon Gamma: Implications for Bladder Cancer Prognosis and Immunotherapy
by: Simon C. Baker, et al.
Published: (2022-10-01)

The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis
by: Qiuqiu Qiu, et al.
Published: (2022-11-01)

Culture-proven disseminated Mycobacterium Bovis infection (BCG-Osis) following intravesical BCG immunotherapy in a patient with bladder carcinoma-in-situ: ‘Case report’
by: Ahmed Ghonaimy, et al.
Published: (2022-02-01)

Bibliometric analysis of immunotherapy for bladder cancer: A correspondence
by: Ruochen Bao, et al.
Published: (2024-12-01)

BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
by: Sarah Lidagoster, et al.
Published: (2024-02-01)

Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
by: Hakeem Sam, et al.
Published: (2020-12-01)

Comparison of the efficacy of BCG intravesical immunotherapy using the conventional Rotisserie method with the non-Rotisserie method
by: Mohammad Kazem Hariri, et al.
Published: (2023-10-01)

Multisystemic BCGitis: A rare complication of intravesical BCG immunotherapy for bladder cancer
by: Ana T. Vilares, MD, et al.
Published: (2022-07-01)

Potentiation of the therapeutic effect of intravesical BCG through synthetic and biogenic selenium nanoparticles in a nitrosamine-induced bladder cancer mouse model
by: Ramak Ajideh, et al.
Published: (2022-12-01)

AIM2 inflammasome activation benefits the therapeutic effect of BCG in bladder carcinoma
by: Houhong Zhou, et al.
Published: (2022-10-01)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
by: Chun Jye Lim, et al.
Published: (2021-01-01)

Vascular graft infections caused by Mycobacterium bovis BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature
by: Stefania Arsuffi, et al.
Published: (2023-05-01)

Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
by: Wojciech Krajewski, et al.
Published: (2020-10-01)

Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors
by: Kai Sun, et al.
Published: (2021-11-01)

Does restaging transurethral resection of bladder tumor influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years’ experience
by: Wojciech Krajewski, et al.
Published: (2018-12-01)

Evaluating the need for transurethral bladder biopsy at first follow up after intravesical BCG therapy for superficial bladder cancer: Preliminary data
by: K. Mursi, et al.
Published: (2012-03-01)

PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy
by: Moritz Maas, et al.
Published: (2024-03-01)

Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer
by: Julieti Huch Buss, et al.
Published: (2018-01-01)

What have we learned after 30 years of BCG intravesical therapy for superficial bladder cancer?
by: Marcos Tobias-Machado, et al.
Published: (2009-12-01)

Systematic Review and Meta-Analysis of Response Rates in BCG-unresponsive Non–Muscle-Invasive Bladder Cancer: a Consensus Statement From the International Bladder Cancer Group
by: Kyle M. Rose, et al.
Published: (2022-09-01)

Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives
by: Mikołaj Wołącewicz, et al.
Published: (2020-05-01)

Pre-therapeutic lymphocytopenia: a new prognostic factor for failure of endovesical BCG-immunotherapy in non-muscle invasive bladder cancer
by: Idriss Ziani, et al.
Published: (2023-03-01)

Knowledge-map analysis of bladder cancer immunotherapy
by: Zongwei Lv, et al.
Published: (2023-12-01)

Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
by: Vivek Sharma, et al.
Published: (2020-12-01)

Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
by: Francesco Del Giudice, et al.
Published: (2022-02-01)

A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues
by: Yi Huang, et al.
Published: (2024-02-01)

A case of disseminated M. bovis bacillus Calmette-Guérin (BCG) disease after one month of BCG bladder infusion therapy and analysis of 77 cases of suspected BCG infection in Japan, 2017–2022
by: Masashi Nishimura, et al.
Published: (2023-01-01)

Management of Hepatic Granulomatous Tuberculosis After BCG Therapy for Bladder Cancer
by: Mohsen Ayati, et al.
Published: (2017-07-01)

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
by: Francesco Del Giudice, et al.
Published: (2023-03-01)

Study of BCG immunotherapy in the management of multiple, extensive non-genital cutaneous common warts
by: Angoori Gnaneshwar Rao, et al.
Published: (2020-01-01)

Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy
by: Raffaella Rossi, et al.
Published: (2013-12-01)

Pott's disease post intravesical BCG
by: Anika Jain
Published: (2023-01-01)

Perianal Plasmoacanthoma After BCG-Immunotherapy: Case Report and Review of Literature
by: Masoumeh Roohaninasab, et al.
Published: (2022-07-01)

Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507)
by: Jake Tempo, et al.
Published: (2023-11-01)

Nonmuscle invasive bladder cancer: a primer on immunotherapy
by: Mahir Maruf, et al.
Published: (2016-06-01)

Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021
by: Long Ma, et al.
Published: (2022-03-01)

Quality analysis of BCG vaccine for bladder cancer immunotherapy using Shewhart control charts
by: A. A. Savina, et al.
Published: (2024-03-01)

In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment
by: Dunia Rodriguez, et al.
Published: (2019-06-01)